Diabetes and the Small Intestine

Area of Science:

• Gastroenterology
• Endocrinology
• Diabetology

Background:

• Diabetes mellitus (DM) complications are rising, including diabetic enteropathy (DE), which causes diverse gastrointestinal symptoms.
• Traditionally attributed to vagal autonomic neuropathy, DE's cause is now linked to hyperglycemia-induced oxidative stress impacting neural networks like nitrergic neurons and interstitial cells of Cajal (ICC).
• DE affects most diabetes patients, yet early diagnostic tools and targeted therapies remain scarce, delaying crucial interventions.

Purpose of the Study:

• To review the current understanding of diabetic enteropathy (DE) pathophysiology.
• To highlight the limitations in early diagnosis and treatment of DE.
• To emphasize the need for further research into DE's underlying mechanisms and novel therapeutic strategies.

Main Methods:

• Literature review of current theories on DE development.
• Analysis of existing diagnostic modalities for DE.
• Examination of current and emerging treatment options for DE.

Main Results:

• Hyperglycemia and oxidative stress are increasingly recognized as central to DE pathogenesis, affecting neural and cellular networks in the gut.
• Diagnostic tools like manometry, wireless motility capsule, and scintigraphy are underutilized in clinical practice due to availability issues.
• Symptomatic treatments like rifaximin and somatostatin analogues are available, but research into stem cell therapy and microbiome alterations shows promise for future interventions.

Conclusions:

• Early recognition of DE is critical to manage symptoms and prevent irreversible small bowel complications like dysmotility and malabsorption.
• Significant gaps exist in the early diagnosis and targeted treatment of DE, necessitating further research.
• Novel therapeutic approaches targeting the pathologic underpinnings of DE are urgently needed.